insights_auto
Per què FARN ha baixat 5,67%?
Aprofundeix méschevron_right
FARN:LON
Faron Pharmaceuticals Oy
28,30 GBX
arrow_downward
-5,67%(-1,70) 1d
12 de nov., 16:30:00 UTC · GBX
search
Tots els símbols
| Símbol | Preu | Canvi | Percentatge de canvi |
|---|
insights_autoS'estan generant les estadístiques principals per a FARN...
Obre
28,35 GBX
Alt
30,60 GBX
Baix
28,00 GBX
Capitalització borsària
58,33 M
Volum mitjà
42,86 k
Volum
23,00 k
Alt 52 setmanes
188,97 GBX
Baix 52 setmanes
28,00 GBX
BPA
-0,10 GBX
Accions en circulació
31,03 M
Nombre d'empleats
36
Obre
28,35 GBX
Alt
30,60 GBX
Baix
28,00 GBX
Capitalització borsària
58,33 M
Volum mitjà
42,86 k
Volum
23,00 k
Alt 52 setmanes
188,97 GBX
Baix 52 setmanes
28,00 GBX
BPA
-0,10 GBX
Accions en circulació
31,03 M
Nombre d'empleats
36
Notícies
De fonts web i partners de notícies
Invezz
·
fa 8 hores
VOO & Chill gana impulso: ¿Qué sigue para el S&P 500?
Comercio TV
·
fa 4 hores
S&P 500 se desploma por la salida de Jensen Huang de Nvidia: Wall Street teme una crisis mayor
BeInCrypto
·
fa 12 hores
El S&P 500 está a 2.5% de un nuevo ATH: ¿Le seguirá Bitcoin?
Perfil
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
Sobre Faron Pharmaceuticals Oy
Conseller delegatMarkku Jalkanen
Empleats36
Fundació2003
Seu principal-
SectorHealth Care
Sector-
Lloc webfaron.com